Halozyme Therapeutics, Inc. (HALO) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon. My name is Melissa, and I will be your conference operator today. At this time, I would like to welcome everyone to Halazime's first quarter 2026 Financial and Operating Results Conference Call. Please note, this event is being recorded. I will now turn the call over to Tram Bui, Halazime's Vice President of Investor Relations and Corporate Communications. Please go ahead. Thank you, operator. Good afternoon, and welcome to our first quarter 2026 financial and operating results conference call. In addition to the press release issued today after the market closed, you can find a supplementary slide presentation that will be referenced during today's call in the investor relations section of our website. Leading the call will be Dr. Helen Torley, Halazim's president and chief executive officer, who will provide an update on our business, and David Ramsey, our interim chief financial officer, will review our financial results as well as our outlook. On today's call, we will be making forward-looking statements as outlined on slide two. I would also refer you to our SEC filings for a full list of risks and uncertainties. During the call, both GAAP and non-GAAP financial measures will be discussed. Certain non-GAAP or adjusted financial measures are reconciled with the comparable GAAP financial measures in our earnings press release and slide presentation. I will now turn the call over to Dr. Helen Torley, and we will start on slide three. Thank you, Tram, and good afternoon, everyone. We started 2026 with exceptional momentum. The continued strong performance of our currently approved products gives us strong conviction in the 2026 to 2028 financial guidance. Our recent New Deal momentum and new nominations by partners, accompanied by the expanding numbe...